Research Institute of Human Morphology, Moscow, Russia.
Bull Exp Biol Med. 2020 Feb;168(4):533-537. doi: 10.1007/s10517-020-04748-2. Epub 2020 Mar 9.
We studied morphological changes in the prostate ventral lobe, proliferative activity of the epithelium in prostate acini, and the levels of prolactin and prostate-specific antigen in the blood serum of Sprague-Dawley rats after repeated injections of sulpiride in a dose of 40 mg/ kg over 30 and 60 days and in 10 and 30 days after withdrawal. Morphological and morphometrical analysis of hyperplastic changes in the prostate ventral lobe was performed. Ki-67 proliferating epithelial cells in the acini were counted. The dynamics of serum concentrations of prolactin and prostate-specific antigen was evaluated by ELISA. Morphological and morphometrical analysis and evaluation of the content of Ki-67 cells demonstrated epithelium hyperplasia in the prostate ventral lobe after sulpiride treatment for 30 or 60 days and in 10 days after withdrawal, but serum level of prostate-specific antigen did not differ from the control. After 60-day sulpiride treatment and in 30 days after withdrawal, pronounced hyperplastic changes of prostate and elevated concentrations of prostate-specific antigen (but not prolactin) were observed. Thus, administration of sulpiride (40 mg/kg) to Sprague-Dawley rats for 60 days allows, by morphological criteria and serum level of prostate-specific antigen, to model stable hyperplastic changes in the prostate corresponding to benign prostatic hyperplasia in humans.
我们研究了 Sprague-Dawley 大鼠在重复注射剂量为 40mg/kg 的舒必利 30 天和 60 天以及停药 10 天和 30 天后，前列腺腹叶的形态变化、前列腺腺泡上皮的增殖活性以及血清中催乳素和前列腺特异性抗原的水平。对前列腺腹叶的增生变化进行了形态学和形态计量学分析。计数了腺泡中 Ki-67 增殖的上皮细胞。通过 ELISA 评估了催乳素和前列腺特异性抗原血清浓度的动态。形态学和形态计量学分析以及 Ki-67 细胞含量的评估表明，舒必利治疗 30 天或 60 天以及停药 10 天后，前列腺腹叶的上皮细胞增生，但前列腺特异性抗原的血清水平与对照组无差异。在 60 天的舒必利治疗和停药 30 天后，观察到前列腺明显增生和前列腺特异性抗原（而非催乳素）浓度升高。因此，给 Sprague-Dawley 大鼠连续 60 天给予 40mg/kg 的舒必利可以根据形态学标准和前列腺特异性抗原的血清水平，模拟与人的良性前列腺增生相对应的前列腺稳定增生变化。
